DDrare: Database of Drug Development for Rare Diseases

Comparator: ezetimibe (DrugBank: Ezetimibe)

2 diseases

ID	Disease name (Link within this page)	Number of trials
79	Homozygous familial hypercholesterolemia	1
260	Sitosterolemia	1

79. Homozygous familial hypercholesterolemia [ 128 clinical trials, 105 drugs, (DrugBank: 29 drugs), 8 drug target genes, 15 drug target pathways]

Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 128 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00092833 (ClinicalTrials.gov)	July 2002	23/9/2004	Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)	An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia	Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors	Drug: Comparator: ezetimibe	Merck Sharp & Dohme Corp.	NULL	Terminated	8 Years	N/A	All	49	Phase 3	United States

260. Sitosterolemia [ 13 clinical trials, 13 drugs, (DrugBank: 4 drugs), 1 drug target gene, 1 drug target pathway]

Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 13 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00092833 (ClinicalTrials.gov)	July 2002	23/9/2004	Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)	An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia	Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors	Drug: Comparator: ezetimibe	Merck Sharp & Dohme Corp.	NULL	Terminated	8 Years	N/A	All	49	Phase 3	United States